GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives $9.36 Consensus Price Target from Brokerages

GoodRx Holdings, Inc. (NASDAQ:GDRX) has been assigned a consensus rating of “Moderate Buy” from the fifteen brokerages that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $9.36.

A number of equities research analysts have recently issued reports on GDRX shares. Citigroup cut their target price on GoodRx from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. UBS Group reduced their price objective on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a research note on Friday, August 9th. Raymond James upgraded shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price target on the stock in a report on Friday, August 9th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $10.00 price target on shares of GoodRx in a research report on Friday, August 16th.

GoodRx Stock Up 2.9 %

Shares of NASDAQ GDRX opened at $6.11 on Friday. GoodRx has a 1 year low of $4.14 and a 1 year high of $9.26. The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.96. The stock has a fifty day moving average price of $7.05 and a two-hundred day moving average price of $7.54.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). The business had revenue of $200.60 million for the quarter, compared to the consensus estimate of $200.47 million. GoodRx had a negative net margin of 7.57% and a positive return on equity of 3.63%. The business’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same quarter last year, the business posted $0.02 EPS. As a group, equities analysts forecast that GoodRx will post 0.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total value of $83,921.22. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 4.17% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of GDRX. Cornercap Investment Counsel Inc. increased its position in shares of GoodRx by 1.7% during the second quarter. Cornercap Investment Counsel Inc. now owns 75,269 shares of the company’s stock valued at $587,000 after purchasing an additional 1,266 shares during the period. California State Teachers Retirement System grew its position in GoodRx by 5.1% during the 1st quarter. California State Teachers Retirement System now owns 70,912 shares of the company’s stock worth $503,000 after acquiring an additional 3,444 shares during the last quarter. US Bancorp DE increased its holdings in GoodRx by 3.7% during the 1st quarter. US Bancorp DE now owns 109,818 shares of the company’s stock valued at $780,000 after purchasing an additional 3,877 shares in the last quarter. Beacon Capital Management LLC bought a new position in GoodRx in the 1st quarter valued at $28,000. Finally, nVerses Capital LLC acquired a new position in GoodRx in the third quarter worth $33,000. 63.77% of the stock is currently owned by institutional investors and hedge funds.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.